At the time of writing, LENZ Therapeutics Inc [LENZ] stock is trading at $18.59, up 11.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LENZ shares have gain 13.98% over the last week, with a monthly amount glided 2.48%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on March 18, 2025, and set its price target to $60. On September 27, 2024, Raymond James initiated with an Outtperform rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $38 on August 12, 2024. William Blair initiated its recommendation with an Outtperform. Leerink Partners started tracking with an Outtperform rating for this stock on April 15, 2024, and assigned it a price target of $32. In a note dated April 10, 2024, Citigroup initiated a Buy rating and provided a target price of $34 on this stock.
For the past year, the stock price of LENZ Therapeutics Inc fluctuated between $14.43 and $50.40. Currently, Wall Street analysts expect the stock to reach $61.5 within the next 12 months. LENZ Therapeutics Inc [NASDAQ: LENZ] shares were valued at $18.59 at the most recent close of the market. An investor can expect a potential return of 230.82% based on the average LENZ price forecast.
Analyzing the LENZ fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -3.88%, Pretax Profit Margin comes in at -3.34%, and Net Profit Margin reading is -3.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.3 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that LENZ Therapeutics Inc [NASDAQ:LENZ] has a current ratio of 12.69. As well, the Quick Ratio is 12.63, while the Cash Ratio is 1.56. Considering the valuation of this stock, the price to sales ratio is 33.24, the price to book ratio is 2.74.
Transactions by insiders
Recent insider trading involved Olsson Shawn, Chief Commercial Officer, that happened on Nov 17 ’25 when 10000.0 shares were sold. Officer, SHAWN OLSSON completed a deal on Nov 17 ’25 to buy 40000.0 shares. Meanwhile, Director MCCOLLUM JAMES W bought 10500.0 shares on Nov 07 ’25.
